CEFTAZIDIME

N/A

Manufactured by Hospira, Inc.

14,861 FDA adverse event reports analyzed

Last updated: 2026-04-14

About CEFTAZIDIME

CEFTAZIDIME is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hospira, Inc.. The most commonly reported adverse reactions for CEFTAZIDIME include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, SEPTIC SHOCK, CONDITION AGGRAVATED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CEFTAZIDIME.

Top Adverse Reactions

DRUG INEFFECTIVE827 reports
OFF LABEL USE657 reports
PYREXIA533 reports
SEPTIC SHOCK334 reports
CONDITION AGGRAVATED319 reports
NEUTROPENIA317 reports
PNEUMONIA294 reports
ACUTE KIDNEY INJURY293 reports
DIARRHOEA293 reports
FEBRILE NEUTROPENIA268 reports
HYPOTENSION264 reports
SEPSIS262 reports
RESPIRATORY FAILURE253 reports
NAUSEA248 reports
DYSPNOEA244 reports
VOMITING228 reports
THROMBOCYTOPENIA222 reports
APLASTIC ANAEMIA217 reports
ANAEMIA214 reports
ENDOPHTHALMITIS192 reports
RENAL FAILURE183 reports
MUCOSAL INFLAMMATION180 reports
PANCYTOPENIA179 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME174 reports
RASH172 reports
DRUG RESISTANCE170 reports
DRUG INTERACTION168 reports
RENAL IMPAIRMENT163 reports
ASTHENIA159 reports
PRODUCT USE IN UNAPPROVED INDICATION159 reports
PATHOGEN RESISTANCE153 reports
PLATELET COUNT DECREASED149 reports
DEATH145 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS143 reports
ABDOMINAL PAIN134 reports
PSEUDOMONAS INFECTION132 reports
PAIN128 reports
RENAL FAILURE ACUTE127 reports
ALANINE AMINOTRANSFERASE INCREASED123 reports
INFECTION116 reports
COUGH114 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION114 reports
DECREASED APPETITE113 reports
HYPERBILIRUBINAEMIA111 reports
MALAISE111 reports
WHITE BLOOD CELL COUNT DECREASED111 reports
EYE PAIN109 reports
RASH MACULO PAPULAR109 reports
LEUKOPENIA108 reports
TOXIC EPIDERMAL NECROLYSIS108 reports
DISEASE PROGRESSION106 reports
HYPOKALAEMIA106 reports
HEADACHE105 reports
PLEURAL EFFUSION105 reports
CONFUSIONAL STATE102 reports
PRODUCT USE ISSUE101 reports
TOXICITY TO VARIOUS AGENTS99 reports
BLOOD CREATININE INCREASED98 reports
WEIGHT DECREASED98 reports
CHOLESTASIS95 reports
DRUG HYPERSENSITIVITY95 reports
ASCITES94 reports
DISSEMINATED INTRAVASCULAR COAGULATION94 reports
MULTI ORGAN FAILURE94 reports
CHILLS93 reports
VISUAL ACUITY REDUCED93 reports
ASPARTATE AMINOTRANSFERASE INCREASED92 reports
C REACTIVE PROTEIN INCREASED92 reports
FATIGUE90 reports
HYPERTENSION90 reports
TACHYCARDIA89 reports
EOSINOPHILIA88 reports
CARDIAC ARREST84 reports
BLOOD BILIRUBIN INCREASED83 reports
GENERAL PHYSICAL HEALTH DETERIORATION83 reports
HYPERSENSITIVITY83 reports
NEUTROPHIL COUNT DECREASED83 reports
HYPOXIA80 reports
URINARY TRACT INFECTION80 reports
HAEMOGLOBIN DECREASED79 reports
PRURITUS78 reports
RESPIRATORY DISTRESS78 reports
CHOROIDITIS76 reports
HEPATIC FUNCTION ABNORMAL76 reports
STAPHYLOCOCCAL INFECTION75 reports
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS74 reports
OEDEMA PERIPHERAL74 reports
FOETAL EXPOSURE DURING PREGNANCY73 reports
HYPONATRAEMIA73 reports
CARDIAC FAILURE71 reports
CHEST PAIN71 reports
DEPRESSION71 reports
PERITONITIS71 reports
CLOSTRIDIUM DIFFICILE COLITIS69 reports
DEHYDRATION69 reports
ERYTHEMA69 reports
GAMMA GLUTAMYLTRANSFERASE INCREASED69 reports
NEUROPATHY PERIPHERAL69 reports
STOMATITIS69 reports
COMA68 reports

Report Outcomes

Out of 7,403 classified reports for CEFTAZIDIME:

Serious 95.6%Non-Serious 4.4%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male3,822 (56.2%)
Female2,950 (43.4%)
Unknown23 (0.3%)

Reports by Age

Age 67152 reports
Age 38137 reports
Age 3136 reports
Age 69116 reports
Age 74115 reports
Age 62114 reports
Age 68113 reports
Age 60112 reports
Age 64109 reports
Age 66106 reports
Age 70102 reports
Age 9101 reports
Age 6599 reports
Age 7299 reports
Age 5997 reports
Age 7196 reports
Age 7396 reports
Age 1094 reports
Age 7794 reports
Age 5893 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CEFTAZIDIME?

This profile reflects 14,861 FDA FAERS reports that mention CEFTAZIDIME. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CEFTAZIDIME?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, SEPTIC SHOCK, CONDITION AGGRAVATED, NEUTROPENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CEFTAZIDIME?

Labeling and FAERS entries often list Hospira, Inc. in connection with CEFTAZIDIME. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.